HomeBiosimilar Antibodies

Biosimilar Antibodies

Cat.No. Product Name Information Isotype
A3053 Anti-BST2 / CD317 Anti-BST2 / CD317 monoclonal antibody that targets Bone marrow stromal antigen 2. It can be used in cancer research. MW :145.52. KD. Human IgG1
A2798 Certolizumab (Anti-TNFSF2 / TNFa) Certolizumab (anti-TNFSF2 / TNFa) is a Fab fragment of a recombinant, humanized monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) with anti-inflammatory activity. MW: 144.92 kD. Human IgG1
A3054 Anti-Siglec-15 / CD33L3 (AB-25E9) Anti-Siglec-15 / CD33L3 (AB-25E9) is a humanized monoclonal antibody targeting sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15). It may have potential as an anti-resorptive therapy for osteoporosis. MW :150 KD. Human IgG1
A2800 Anti-Amyloid Beta (CNTO 2125) Anti-Amyloid Beta (CNTO 2125) is a human monoclonal antibody against amyloid beta has the potential to be used in Alzheimer's disease (AD) research. MW : 143.86 KD. Human IgG1
A3056 Epratuzumab (Anti-Siglec-2 / CD22) Epratuzumab (Anti-Siglec-2 / CD22) is a IgG4 monoclonal antibody targeting CD22. It has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases. MW: 155.4 KD. Human IgG4SP
A2801 Anti-IL-13 (CNTO 607) Anti-IL-13 (CNTO 607) is a recombinant human antibody against interleukin 13 (IL-13). MW : 144.14 KD. Human IgG1
A3057 Anti-Siglec-2 / CD22 (NCI m971) Anti-Siglec-2 / CD22 (NCI m971) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is used in treatment of acute lymphoblastic leukemia (ALL). MW :146.64 KD. Human IgG1
A2802 Cobolimab (Anti-TIM-3 / HAVCR2 / CD366) Cobolimab (Anti-TIM-3 / HAVCR2 / CD366) is a monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cellular receptor 2; HAVCR2), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 142.84 KD. Human IgG1
A3058 Anti-Siglec-2 / CD22 (NCI m972) Anti-Siglec-2 / CD22 (NCI m972) is a humanized monoclonal antibody targeting CD22, a Siglec family lectin present on B cells. It is a promising novel therapeutics for B-cell acute lymphoblastic leukemia (BCP-ALL). MW :144.3 KD. Human IgG1
A2803 Cofetuzumab (Anti-PTK7 / CCK4) Cofetuzumab (Anti-PTK7 / CCK4) is humanized IgG1 monoclonal antibody against protein tyrosine kinase 7 (PTK7) with potential antitumor activity. MW : 146.7 KD. Human IgG1
A3059 Pinatuzumab (Anti-Siglec-2 / CD22) Pinatuzumab (Anti-Siglec-2 / CD22)a humanized IgG1 monoclonal antibody targeting CD22. It has potential antineoplastic activity and can be used in research of Non-Hodgkin Lymphoma. MW : 146.64 KD. Human IgG1
A2804 Coltuximab (Anti-CD19) Coltuximab (Anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity. MW : 144.7 KD. Human IgG1
A2805 Ripertamab (Anti-CD20) Ripertamab (Anti-CD20) is a chimeric monoclonal antibody directed against human CD20 with potential antineoplastic activity. MW : 144.56 KD. Human IgG1
A3061 Azintuxizumab (Anti-SLAMF7 / CS1) Azintuxizumab (Anti-SLAMF7 / CS1/ CD319/ CRACC) is a monoclonal IgG4 bispecific antibody targeting B-cell maturation antigen (BCMA). It has the potential for the research of relapsed/refractory multiple myeloma (RRMM). MW :140.12 KD. Human IgG1
A2806 Anti-CD20 (TRU-015) Anti-CD20 (TRU-015) is a small proprietary antibody-based single-chain polypeptide that binds to CD20 and effectively depleted B cells. It exhibits anti-tumor activity in human tumor xenograft models. MW : 145.4 KD. Human IgG1
A3062 Anti-SLAMF7 / CS1 Anti-SLAMF7 / CS1 (PDL241) is a novel humanized monoclonal antibody, targeting CD319. It is a promising therapeutic target for rheumatoid arthritis. MW :144.92 KD. Human IgG1
A2807 Ublituximab (Anti-CD20) Ublituximab (Anti-CD20) is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity.  MW : 145.22 KD. Human IgG1
A3063 Anti-SLC2A8 (VB1-050) Anti-SLC2A8 (VB1-050) is amonoclonal antibody ADCC, targeting SLC2A8. It is used in the various cancer treatment including breast, liver, prostate and colon cancers. MW :145.08 KD. Human IgG1
A2808 Veltuzumab (Anti-CD20) Veltuzumab (Anti-CD20) is a humanized monoclonal antibody directed against the CD20 antigen with potential antineoplastic activity. MW : 145.22 KD. Human IgG1
A3064 Solanezumab (Anti-Amyloid Beta) Solanezumab (Anti-Amyloid Beta) is a humanized monoclonal IgG1 antibody targeting the mid-domain of the amyloid-β (Aβ) peptide. It has the potential for the research of Alzheimer’s disease. MW :144.34 KD. Human IgG1